Patents by Inventor Yalda Bravo
Yalda Bravo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364082Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: July 25, 2023Publication date: November 16, 2023Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Patent number: 11795156Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: June 23, 2022Date of Patent: October 24, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Patent number: 11752149Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: GrantFiled: November 24, 2020Date of Patent: September 12, 2023Assignee: Pipeline Therapeutics, Inc.Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Patent number: 11738009Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: April 17, 2018Date of Patent: August 29, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Patent number: 11638704Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: June 22, 2021Date of Patent: May 2, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Publication number: 20230089921Abstract: Provided herein, inter alia, are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: October 6, 2020Publication date: March 23, 2023Inventors: Jill Melissa Baccei, Yalda Bravo, Austin Chih-Yu Chen, Jeffrey Roppe, Thomas Schrader, Yifeng Xiong
-
Publication number: 20230045612Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: June 23, 2022Publication date: February 9, 2023Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG
-
Patent number: 11512090Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: GrantFiled: June 10, 2019Date of Patent: November 29, 2022Assignee: Pipeline Therapeutics, Inc.Inventors: Yifeng Xiong, Thomas Schrader, Austin Chen, Jeffrey Roger Roppe, Jill Melissa Baccei, Yalda Bravo
-
Publication number: 20220332721Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: June 10, 2019Publication date: October 20, 2022Inventors: Yifeng XIONG, Thomas SCHRADER, Austin CHEN, Jeffrey Roger ROPPE, Jill Melissa BACCEI, Yalda BRAVO
-
Patent number: 11472789Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: October 14, 2020Date of Patent: October 18, 2022Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Patent number: 11440897Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: October 14, 2020Date of Patent: September 13, 2022Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Publication number: 20210387985Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Publication number: 20210363152Abstract: The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 10, 2019Publication date: November 25, 2021Inventors: Jill Melissa Baccei, Yalda Bravo, Austin Chih-Yu Chen, Ryan Christopher Clark, Brian Andrew Stearns, Yen Pham Hong Truong
-
Patent number: 11066405Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: May 21, 2020Date of Patent: July 20, 2021Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Publication number: 20210161889Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: ApplicationFiled: November 24, 2020Publication date: June 3, 2021Inventors: Yifeng Xiong, Jeffrey Roppe, Austin Chih-Yu Chen, Yalda Bravo, Thomas Schrader, Jill Melissa Baccei
-
Patent number: 10968201Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: April 17, 2019Date of Patent: April 6, 2021Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Publication number: 20210024491Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: October 14, 2020Publication date: January 28, 2021Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG
-
Publication number: 20210008046Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: April 17, 2018Publication date: January 14, 2021Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Publication number: 20200283438Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: May 21, 2020Publication date: September 10, 2020Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Patent number: 10710959Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.Type: GrantFiled: December 28, 2018Date of Patent: July 14, 2020Assignee: NOVIRA THERAPEUTICS, INC.Inventors: Austin Chen, Yalda Bravo, Nicholas Stock, Bijan Pedram, Jason Jacintho, Ryan C. Clark